Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDK-b
- Development stage
- Preclinical
- Lead developer
- PRISM BioLab
- Modality
- Small Molecules
01
Overview
CDK-b is a preclinical-stage small molecule program developed by PRISM BioLab for the treatment of oncology. The program utilizes PRISM's proprietary PepMetics technology, which involves the design of small molecules that mimic the alpha-helix or beta-turn structures of proteins to modulate protein-protein interactions (PPIs). CDK-b is specifically designed to inhibit the interaction between a cyclin-dependent kinase (CDK) and its regulatory cyclin subunit. By disrupting this PPI, the drug aims to inhibit the enzymatic activity of the CDK/Cyclin complex, thereby blocking cell cycle progression in malignant cells. The program is currently in the hit identification phase of development.
02
Targets
Cyclin-dependent kinase–cyclin complex
Beyond the preview
Go deeper on CDK-b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDK-b.